Lorbrena is called Lorbiqua or Lorbriqua internationally. Save over 68% on brand name medicine by Pfizer!
EU Lorviqua is manufactured at:
Pfizer Manufacturing Deutschland GmbH
BetriebsstÓ“tte Freiburg
Mooswaldallee 1
79090 Freiburg
Germany
Lorbriqua is manufactured at above address or alternatively at:
Pfizer Pharmaceuticals LLC; KM 1.9 Road 689, Vega Baja, Puerto Rico - 00693,
United States (USA)
- EU APPROVAL - showing manufacturing site
- Lorbriqua - Pfizer medicine insert showing manufacturing in German or USA for Lorbriqua
Information about Lorbriqua (Lorlatinib)
Lorbriqua is an oral medication classified as a tyrosine kinase inhibitor, specifically designed to target certain types of cancer. It is primarily used for treating non-small cell lung cancer (NSCLC) that is ALK-positive.
Product Highlights
- Treatment of adult patients with locally advanced or metastatic NSCLC that is confirmed to be ALK-positive, particularly after the failure of other ALK inhibitors.
Key Ingredient
Key Benefits
- Provides an effective treatment option for patients with ALK-positive NSCLC who have experienced progression on other therapies.
- Potentially improves survival rates and quality of life.
- Offers the ability to manage brain metastases due to its CNS penetrative properties.
Direction of Use
- Take Lorbriqua exactly as directed by your healthcare provider.
- The recommended dosage is one tablet once daily, regardless of meals.
- Swallow the tablet whole; do not crush or chew it.
- Follow instructions on handling missed doses as advised by your healthcare provider.
Safety Concerns
- Common side effects may include fatigue, nausea, diarrhea, and changes in liver enzyme levels.
- Serious risks may involve pneumonitis, hyperlipidemia, and neurological effects.
- Regular assessment of liver function and lipid levels may be necessary during treatment.
Avoid Lorbriqua (Lorlatinib) If
- You have a known allergy to lorlatinib or any of its inactive ingredients.
- You have severe liver impairment.
- You are taking medications that could interact adversely with lorlatinib, unless specifically directed by a healthcare provider.
- You are pregnant, planning to become pregnant, or breastfeeding, as it may pose risks to the fetus or infant.
